New CDK4/6 Strategies in HR+/HER2– Breast Cancer: Imlunestrant ± Abemaciclib and the Avutometinib Triplet

n

Hormone receptor–positive, HER2-negative (HR+/HER2–) metastatic breast cancer is the most common subtype of advanced breast cancer. Over the past decade, the introduction of CDK4/6 inhibitors has significantly improved outcomes when combined with endocrine therapy. However, disease progression eventually occurs in most patients. After resistance develops, choosing the next effective treatment remains a major clinical challenge.

Two recent clinical trials are exploring new post–CDK4/6 strategies in HR+/HER2 metastatic breast cancer. One focuses on the oral selective estrogen receptor degrader (SERD) Imlunestrant, given alone or in combination with Abemaciclib. 

The other investigates a novel triplet regimen that includes Avutometinib, abemaciclib, and fulvestrant.

Together, these studies provide important insight into how treatment may evolve after CDK4/6 inhibitor resistance.

Understanding CDK4/6 Resistance in HR+/HER2– Breast Cancer

First-line treatment for HR+/HER2 metastatic breast cancer typically includes endocrine therapy combined with a CDK4/6 inhibitor such as abemaciclib, palbociclib, or ribociclib. These combinations delay disease progression and improve overall survival.

Despite these benefits, resistance eventually develops. Some tumors acquire ESR1 mutations, which allow cancer cells to activate the estrogen receptor pathway even in the presence of endocrine therapy.

Other tumors activate alternative signaling pathways such as the RAF/MEK/MAPK pathway, helping cancer cells bypass estrogen dependence.

Because of this, researchers are exploring two main strategies:

1. Better estrogen receptor targeting (such as oral SERDs).
2. Blocking additional signaling pathways that drive resistance.

Phase 3 Evidence: Imlunestrant With or Without Abemaciclib (EMBER-3 Trial)

The phase 3 EMBER-3 trial evaluated imlunestrant as monotherapy and in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer who had previously received aromatase inhibitors, with or without prior CDK4/6 inhibitors.

This large, randomized, open-label study enrolled 874 patients between October 2021 and November 2023. Patients were assigned to:

• Imlunestrant alone
• Imlunestrant plus abemaciclib
• Standard-of-care (SOC) endocrine therapy (exemestane or fulvestrant)

Imlunestrant was given at 400 mg orally once daily. Abemaciclib was given at 150 mg orally twice daily.

Progression-Free Survival (PFS) Results

Progression-free survival (PFS) was a primary endpoint.

Among patients with ESR1 mutations:

• Median PFS was 5.5 months with imlunestrant
• 3.8 months with standard endocrine therapy
• Hazard ratio (HR) 0.62

This showed a statistically significant improvement.

In the overall population:

• Median PFS was 10.9 months with imlunestrant plus abemaciclib
• 5.5 months with imlunestrant alone
• HR 0.59

Importantly, this PFS benefit was seen regardless of ESR1 mutation status.

Among patients previously treated with a CDK4/6 inhibitor:

• Median PFS was 9.1 months with the combination
• 3.7 months with imlunestrant alone
• HR 0.53

These results suggest that combining imlunestrant with abemaciclib may restore disease control even after prior CDK4/6 exposure.

Overall Survival (OS) Findings

At 50% OS maturity in ESR1-mutated patients:

• Median OS was 34.5 months with imlunestrant
• 23.1 months with SOC
• HR 0.60

Although some OS data were not yet mature enough for statistical analysis, investigators described the 11.4-month improvement as clinically meaningful.

For the combination arm:

• Median OS was not reached at the interim analysis
• 34.4 months with imlunestrant alone
• HR 0.82 (not statistically significant at this time)

A longer follow-up is needed to determine the full impact on survival.

Time to Chemotherapy (TTC) and PFS2

The EMBER-3 study also showed improvement in secondary endpoints:

Time to chemotherapy (TTC):

• 15.6 months with imlunestrant
• 10.2 months with SOC in ESR1-mutated patients

Among all patients:

• 27.8 months with imlunestrant plus abemaciclib
• 15.5 months with imlunestrant alone

PFS2 (second progression):

• 19.2 months vs 13.5 months in ESR1-mutated patients
• 22.6 months vs 18.5 months in the overall population (combination vs monotherapy)

These findings suggest durable disease control.

Safety Profile

Safety was consistent with known side effects of imlunestrant and abemaciclib. No new safety signals were observed.

Common side effects aligned with expectations for endocrine therapy and CDK4/6 inhibitors. Overall, the regimens were considered manageable.

Regulatory Impact

Based on primary PFS data from EMBER-3, the U.S. Food and Drug Administration approved single-agent imlunestrant in September 2025 for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on at least one line of endocrine therapy.

This approval provides a new, all-oral, chemotherapy-free option for patients with ESR1 mutations.

Ongoing research includes the phase 3 EMBER-4 trial evaluating the immunostimulant in early-stage breast cancer.

Study Snapshot: EMBER-3 vs Avutometinib Triplet Trial

Early-Phase Innovation: The Avutometinib Triplet Strategy

While immunotherapeutic data constitute late-phase evidence, another strategy targets alternative resistance pathways.

The phase 1 trial presented at the 2025 AACR Annual Meeting evaluated a triplet combination:

• Avutometinib (RAF/MEK inhibitor)
• Abemaciclib
• Fulvestrant

This study enrolled patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Scientific Rationale

After CDK4/6 inhibitor resistance, some tumors activate the RAF/MEK/MAPK pathway. Avutometinib is designed to block RAF and MEK signaling.

Combining this agent with abemaciclib and fulvestrant aims to:

• Continue estrogen receptor suppression
• Maintain CDK4/6 blockade
• Block downstream signaling escape pathways

Phase 1 Study Design

Seventeen patients were registered; 16 received treatment.

Dose-finding used a Bayesian optimal interval design to determine the maximum tolerated dose.

The recommended phase 2 dose was:

• Abemaciclib 100 mg twice daily
• Avutometinib 3.2 mg twice weekly
• Fulvestrant 500 mg every 28 days

Safety Findings

Most treatment-related adverse events were grade 1 or 2.

Common side effects included:

• Elevated creatine phosphokinase (CPK)
• Neutropenia
• Diarrhea
• Fatigue
• Rash

Grade 3 events were limited. No grade 4 or 5 toxicities were reported.

Overall, the safety profile was considered manageable.

Efficacy Signals

Although small and early-phase, the study showed preliminary activity:

• Confirmed objective response rate (ORR): 13.3%
  • 1 complete response
  • 1 partial response
• Stable disease in 46.7%
• Clinical benefit rate at week 24: 26.7%
• Median PFS: 3.6 months

Tumor shrinkage was observed in a subset of patients, supporting biological activity.

Because this was a phase 1 trial, results are exploratory and require validation in larger studies.

Comparing the Two Approaches

The imlunestrant strategy represents phase 3, practice-changing evidence, particularly in ESR1-mutated disease. It provides statistically significant improvements in PFS and clinically meaningful OS signals.

The avutometinib triplet is still investigational. It targets a different resistance pathway and may benefit selected patients in the future.

Key differences:

• Imlunestrant ± abemaciclib: Late-phase, FDA-approved (monotherapy in ESR1-mutated disease)
• Avutometinib triplet: Early-phase, hypothesis-generating
• Mechanism: ER degradation vs RAF/MEK pathway inhibition
• Clinical role: Emerging standard vs investigational option

What This Means for Treatment Sequencing

Post–CDK4/6 treatment decisions increasingly rely on molecular testing, especially ESR1 mutation status.

For ESR1-mutated disease, imlunestrant now offers an approved oral option. Combination with abemaciclib may further extend disease control, pending additional data.

For patients without clear endocrine sensitivity, future approaches may involve multi-pathway targeting, as seen with the avutometinib triplet.

Personalized treatment sequencing will likely depend on:

• Mutation testing
• Prior therapy duration
• Patient tolerance
• Clinical trial availability

Looking Ahead

Research continues to refine post–CDK4/6 strategies in HR+/HER2 metastatic breast cancer.

Future directions include:

• Long-term survival follow-up from EMBER-3
• Results from EMBER-4 in early-stage disease
• Larger trials evaluating RAF/MEK-based combinations
• Biomarker-driven treatment selection

The treatment landscape is moving toward more personalized, targeted, and oral regimens designed to delay chemotherapy while maintaining quality of life.

Conclusion

Resistance to CDK4/6 inhibitors remains inevitable in HR+/HER2– metastatic breast cancer. However, emerging strategies are expanding options beyond traditional endocrine therapy.

Phase 3 data support imlunestrant, alone or in combination with abemaciclib, as an effective post–CDK4/6 strategy, particularly in ESR1-mutated disease. Meanwhile, early data from the avutometinib triplet highlight the potential of targeting additional resistance pathways.

Together, these advances signal an evolving treatment paradigm focused on overcoming resistance through combination therapy and precision medicine.

References

1) OncLive — “Imulnestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer.”

2) CancerNetwork — “Avutometinib Combo Shows Activity, Safety for HR+/HER2- Breast Cancer”

3) U.S. FDA — “FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer” (Sept 25, 2025)

4) ClinicalTrials.gov — EMBER-3 (NCT04975308): “A Study of Imlunestrant… and Imlunestrant + Abemaciclib…”

5) NEJM (Abstract page) — “Imlunestrant with or without Abemaciclib in Advanced Breast Cancer”